Drug updated on 4/23/2024

Dosage FormInjection (subcutaneous; 600 mcg/2.4 mL [250 mcg/mL])
Drug ClassParathyroid hormone analogs
Ongoing and
Completed Studies


  • Indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy.
  • Indicated for the increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy.
  • Indicated for the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy.

Latest News

loading GIF

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Teriparatide (Forteo) is indicated for the treatment of osteoporosis in postmenopausal women, men with primary or hypogonadal osteoporosis, and individuals undergoing sustained systemic glucocorticoid therapy. It has demonstrated significant efficacy in increasing bone mineral density (BMD) and reducing fracture risk.
  • The study was based on 17 systematic reviews/meta-analyses that compared teriparatide's safety and effectiveness to other treatments for osteoporosis.
  • Teriparatide significantly accelerated early bone union and reduced time to bone union in cases of atypical femoral fractures compared to controls. This suggests its potential role in promoting callus formation and aiding the healing of delayed/non-healing fractures.
  • Compared to bisphosphonates, which have been associated with serious side effects such as atypical femoral fractures (AFF) and osteonecrosis of the jaw (ONJ), teriparatide showed fewer adverse events while fostering direct anabolic effects on bones.
  • Combination therapy involving teriparatide with denosumab proved more effective than monotherapy by enhancing BMD at the lumbar spine & hip without an increased incidence of adverse events; this indicates a synergistic effect when used together.
  • Some studies suggest romosozumab might offer better improvements in BMD than teriparatide, but both had comparable risks regarding serious adverse events.
  • In terms of the safety profile, most studies reported very few or no severe negative side effects from using Forteo; common mild symptoms included pain at the injection site, though it did increase withdrawal rates due to these adversities especially when compared against bisphosphonates/denosumab use.
  • For specific populations: Postmenopausal women saw reductions in vertebral/nonvertebral fracture risks under Forteo treatment - similar benefits were seen among men suffering from osteoporosis, indicating gender-neutral advantages offered by this drug.

Product Monograph / Prescribing Information

Document TitleYearSource
Forteo (teriparatide) Prescribing Information.2021Lilly USA LLC, Indianapolis, IN

Systematic Reviews / Meta-Analyses

Document TitleYearSource
The effect of teriparatide on patients with atypical femur fractures: a systematic review and meta-analysis.2024Archives of Orthopaedic and Trauma Surgery
Efficacy of osteoporosis pharmacological treatments in men: a systematic review and meta-analysis.2023Aging Clinical and Experimental Research
Efficacy and safety of teriparatide in improving fracture healing and callus formation: a systematic review.2023Cureus
Effectiveness and safety of treatments to prevent fractures in people with low bone mass or primary osteoporosis: a living systematic review and network meta-analysis for the American College of Physicians.2023Annals of Internal Medicine
The efficiency and safety of alendronate versus teriparatide for treatment glucocorticoid-induced osteoporosis: a meta-analysis and systematic review of randomized controlled trials.2022PLOS ONE
Efficacy of the combination of teriparatide and denosumab in the treatment of postmenopausal osteoporosis: a meta-analysis.2022Frontiers in Pharmacology
Romosozumab versus teriparatide for the treatment of postmenopausal osteoporosis: a systematic review and meta-analysis through a grade analysis of evidence.2021Orthopaedic Surgery
Applications of teriparatide for alveolar bone regeneration: a systematic review.2021Journal of International Society of Preventative & Community Dentistry
The effect of osteoporosis and its treatment on fracture healing a systematic review of animal and clinical studies.2021Bone Reports
Effects of teriparatide and bisphosphonate on spinal fusion procedure: a systematic review and network meta-analysis.2020PLOS ONE
Comparison between teriparatide and bisphosphonates for improving bone mineral density in postmenopausal osteoporosis patients: a meta-analysis.2020Medicine
The efficacy of teriparatide on lumbar spine bone mineral density, vertebral fracture incidence and pain in post-menopausal osteoporotic patients: a systematic review and meta-analysis.2020Bone Reports
Effects of teriparatide on treatment outcomes in osteoporotic hip and pelvic bone fractures: meta-analysis and systematic review of randomized controlled trials.2020Hip & Pelvis
Teriparatide for treating delayed union and nonunion: a systematic review.2019Journal of Clinical Orthopaedics and Trauma
Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: a meta-analysis.2019International Journal of Surgery
Clinical application of teriparatide in fracture prevention.2019JB&JS Reviews
Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis.2019The Journal of Clinical Endocrinology and Metabolism

Clinical Practice Guidelines